Rutgers, The State University of New Jersey

Princeton University

Sherif Ibrahim

Patrick J Sinko

Lei Shi

Robert K Prud'homme

Howard A Stone

Xiaoping Zhang

Manjeet Deshmukh

Matthew Sean Palombo

Nathalie M Pinkerton

Jieming Gao

Jiandi Wan

Dayuan Gao

The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.

Lung targeting dual drug delivery system

Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.

Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases

Growing community of inventors

Old Bridge, NJ, United States of America

Sherif Ibrahim